4 Healthcare Stock Stories Ensuring Weekend Investment Wellness

GlaxoSmithKline plc (NYSE:GSK): Closing price $50.11

On Friday, GlaxoSmithKline and Genmab A/SĀ announced the submission of a variation to the marketing authorization to the European Medicines Agency for the use of Arzerra (ofatumumab) in combo with an alkylator-based therapy, to be employed for treatment of CLL patients who have not received prior treatment and are inappropriate for fludarabine-based therapy. The submission is based mainly on results from an international, multi-center, randomized Phase IIIĀ evaluation of ofatumumab in combination with chlorambucil versus chlorambucil alone in over 400 patients with previously untreated CLL.

GSK-20131004